Literature DB >> 31872439

Non-Responders to Treatment With Antibodies to the CGRP-Receptor May Profit From a Switch of Antibody Class.

Christian Ziegeler1, Arne May1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31872439     DOI： 10.1111/head.13729

Source DB:  PubMed          Journal:  Headache        ISSN： 0017-8748            Impact factor:   5.887


× No keyword cloud information.
  5 in total

1.  Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study.

Authors:  Hauke Basedau; Lisa-Marie Sturm; Jan Mehnert; Kuan-Po Peng; Marlene Schellong; Arne May
Journal:  Elife       Date:  2022-05-23       Impact factor: 8.713

2.  Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.

Authors:  Maurice T Driessen; Joshua M Cohen; Stephen F Thompson; Oscar Patterson-Lomba; Michael J Seminerio; Karen Carr; Todor I Totev; Rochelle Sun; Erica Yim; Fan Mu; Rajeev Ayyagari
Journal:  J Headache Pain       Date:  2022-05-16       Impact factor: 8.588

Review 3.  European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.

Authors:  Simona Sacco; Faisal Mohammad Amin; Messoud Ashina; Lars Bendtsen; Christina I Deligianni; Raquel Gil-Gouveia; Zaza Katsarava; Antoinette MaassenVanDenBrink; Paolo Martelletti; Dimos-Dimitrios Mitsikostas; Raffaele Ornello; Uwe Reuter; Margarita Sanchez-Del-Rio; Alexandra J Sinclair; Gisela Terwindt; Derya Uluduz; Jan Versijpt; Christian Lampl
Journal:  J Headache Pain       Date:  2022-06-11       Impact factor: 8.588

Review 4.  Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.

Authors:  Eleonora De Matteis; Simona Sacco; Raffaele Ornello
Journal:  Ther Clin Risk Manag       Date:  2022-04-05       Impact factor: 2.423

5.  Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.

Authors:  Lucas Hendrik Overeem; Andreas Peikert; Maxi Dana Hofacker; Katharina Kamm; Ruth Ruscheweyh; Astrid Gendolla; Bianca Raffaelli; Uwe Reuter; Lars Neeb
Journal:  Cephalalgia       Date:  2021-10-13       Impact factor: 6.292
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.